RecruitingNCT06448897
Development of an Imaging Prediction Model for Pelvic Lymph Node Metastasis of Cervical Cancer Using Artificial Intelligence Techniques.
Sponsor
Obstetrics & Gynecology Hospital of Fudan University
Enrollment
4,000 participants
Start Date
Feb 1, 2024
Study Type
OBSERVATIONAL
Conditions
Summary
This study is a retrospective exploratory trial conducted at a single center, aiming to develop and validate a preoperative lymphatic metastasis model for cervical cancer using artificial intelligence deep learning. The model is trained using preoperative imaging and postoperative pathological findings of cervical cancer patients, with the goal of enhancing the accuracy of lymphatic metastasis prediction through preoperative imaging and offering insights for treatment decisions.
Eligibility
Sex: FEMALEMin Age: 18 YearsMax Age: 80 Years
Inclusion Criteria3
- patients with preoperative diagnosis of invasive cervical cancer stage I-III, with any type of pathology, and patients who underwent radical/modified radical cervical cancer surgery + pelvic lymph node dissection in our hospital.
- Age ≥18 years old and ≤80 years old
- patients with complete preoperative pelvic MRI images and postoperative pathology and clinical data in our hospital
Exclusion Criteria6
- Patients during pregnancy or breastfeeding, patients within 42 days of abortion
- Patients who have received neoadjuvant chemotherapy or radiotherapy before surgery for this previous cervical cancer
- Patients with other malignant tumors within 5 years
- Combination of other underlying diseases that may lead to enlarged pelvic lymph nodes
- Imaging report more than 1 month prior to surgery
- Poor image quality and unrecognizable
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06448897
Related Trials
ESPERANZA: External Control Arm Study for T-DXd for Patients With HER2 IHC3+ Solid Tumors
NCT0697316127 locations
GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors
NCT049774538 locations
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
NCT0721670360 locations
A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)
NCT06459180239 locations
Ocular Assessments in Patients Treated With Tivdak® in Recurrent or Metastatic Cervical Cancer
NCT0695266078 locations